Oral Cavity Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
Conditions: Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma; Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 Interventions: Drug: Cyclophosphamide; Biological: IRX-2; Biological: Nivolumab; Procedure: Surgery Sponsors: Emory University; Bristol-Myers Squibb; IRX Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 2, 2018 Category: Research Source Type: clinical trials

Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study
Conditions: Squamous Cell Carcinoma, Head And Neck; Squamous Cell Carcinoma Mouth; Squamous Cell Carcinoma of the Oral Cavity Interventions: Drug: Sitravatinib; Biological: Nivolumab Sponsors: University Health Network, Toronto; Mirati Therapeutics Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 2, 2018 Category: Research Source Type: clinical trials